Prediction of Progression-free Survival for Stage IB-IIA Non-small Cell Lung Cancer Based on CT Morphological Features and Clinicopathological Characteristics
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v5i4.3035
Abstract
Objectives: The aim of this study is to evaluate the feasibility of computed tomography (CT) morphological features and clinicopathological characteristics in predicting progression-free survival (PFS) for patients with stage IB-IIA non-small cell lung cancer (NSCLC). Methods: A total of 95 patients with stage IB-IIA NSCLC who underwent CT scans and surgical resection were retrospectively included in our study. The CT morphological features and clinicopathological characteristics were assessed by two observers. Univariate and multivariate cox proportional hazards regression analysis were used to identify significant PFS predictors and construct prediction model. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the predictive ability of the model for progression-free survival at 1-, 2- and 3-years. In internal validation, the predictive model was subjected to bootstrapping validation (1000 bootstrap resamples) to calculate the overall relative C-index. Results: Progression were found in 17 patients (17.9%, 17/95). Four risk factors were determined in the multiple stepwise Cox regression analysis, including male, age, sublobectomy, and lobulation, as well as CT diameter. The AUC of the model for predicting 1, 2, and 3 years PFS was 0.899, 0.799 and 0.833, respectively. In the internal validation cohort, the overall relative C index of the model was 0.82. The model showed good prediction performance. Conclusion: The model constructed from CT morphological features and clinicopathological characteristics helps predict PFS in patients with stage IB-IIA NSCLC and distinguish between high-risk and low-risk patients, which could help the doctor make Postoperative decisions.
Keywords
non-small cell lung cancer; progression-free survival; computed tomography
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[3] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[4] ETTINGER D S, WOOD D E, AISNER D L, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021 [J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[5] ZHAO F, ZHAO Y, ZHANG Y, et al. Predictability and Utility of Contrast-Enhanced CT on Occult Lymph Node Metastasis for Patients with Clinical Stage IA-IIA Lung Adenocarcinoma: A Double-Center Study [J]. Acad Radiol, 2023, 30(12): 2870-2879.
[6] SUN Q, LI P, ZHANG J, et al. CT Predictors of Visceral Pleural Invasion in Patients with Non-Small Cell Lung Cancers 30 mm or Smaller [J]. Radiology, 2024, 310(1): e231611.
[7] ZHANG Y, SUN Y, XIANG J, et al. A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer [J]. J Thorac Cardiovasc Surg, 2014, 148(4): 1193-1199.
[8] KIM I H, LEE I H, LEE J E, et al. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer [J]. Clin Lung Cancer, 2016, 17(5): e31-e43.
[9] ZHANG N, TAN Q, TAO D, et al. Cytokines screening identifies MIG (CXCL9) for postoperative recurrence prediction in operated non-small cell lung cancer patients [J]. Cytokine, 2022, 149(155759).
[10] ARAK H, AYTEKIN A, CANOZ O, et al. Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience [J]. Turk Patoloji Derg, 2021, 37(3): 239-248.
[11] WANG G, ZHAO M, LI J, et al. m7G-Associated subtypes, tumor microenvironment, and validation of prognostic signature in lung adenocarcinoma [J]. Front Genet, 2022, 13(954840).
[12] WU P, ZHENG Y, WANG Y, et al. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma [J]. J Transl Med, 2020, 18(1): 380.
[13] ZENG B, JI P, CHEN C, et al. A nomogram from the SEER database for predicting the prognosis of patients with non-small cell lung cancer [J]. Int J Biochem Cell Biol, 2020, 127(105825).
[14] LIU Y, HUANG C, LIU H, et al. Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study [J]. World J Surg Oncol, 2014, 12(138).
[15] ZHANG X X, LI R, FAN L H, et al. Prognostic predictors of radical resection of stage I-IIIB non-small cell lung cancer: the role of preoperative CT texture features, conventional imaging features, and clinical features in a retrospectively analyzed [J]. BMC Pulmonary Medicine, 2023, 23 (1): 122.
[16] ZHANG Y, QIANG J W, YE J D, et al. High resolution CT in differentiating minimally invasive component in early lung adenocarcinoma [J]. Lung Cancer, 2014, 84(3): 236-41.
[17] SHIMIZU K, YAMADA K, SAITO H, et al. Surgically curable peripheral lung carcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival [J]. Chest, 2005, 127(3): 871-8.
[2] SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023 [J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[3] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.
[4] ETTINGER D S, WOOD D E, AISNER D L, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021 [J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[5] ZHAO F, ZHAO Y, ZHANG Y, et al. Predictability and Utility of Contrast-Enhanced CT on Occult Lymph Node Metastasis for Patients with Clinical Stage IA-IIA Lung Adenocarcinoma: A Double-Center Study [J]. Acad Radiol, 2023, 30(12): 2870-2879.
[6] SUN Q, LI P, ZHANG J, et al. CT Predictors of Visceral Pleural Invasion in Patients with Non-Small Cell Lung Cancers 30 mm or Smaller [J]. Radiology, 2024, 310(1): e231611.
[7] ZHANG Y, SUN Y, XIANG J, et al. A clinicopathologic prediction model for postoperative recurrence in stage Ia non-small cell lung cancer [J]. J Thorac Cardiovasc Surg, 2014, 148(4): 1193-1199.
[8] KIM I H, LEE I H, LEE J E, et al. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer [J]. Clin Lung Cancer, 2016, 17(5): e31-e43.
[9] ZHANG N, TAN Q, TAO D, et al. Cytokines screening identifies MIG (CXCL9) for postoperative recurrence prediction in operated non-small cell lung cancer patients [J]. Cytokine, 2022, 149(155759).
[10] ARAK H, AYTEKIN A, CANOZ O, et al. Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience [J]. Turk Patoloji Derg, 2021, 37(3): 239-248.
[11] WANG G, ZHAO M, LI J, et al. m7G-Associated subtypes, tumor microenvironment, and validation of prognostic signature in lung adenocarcinoma [J]. Front Genet, 2022, 13(954840).
[12] WU P, ZHENG Y, WANG Y, et al. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma [J]. J Transl Med, 2020, 18(1): 380.
[13] ZENG B, JI P, CHEN C, et al. A nomogram from the SEER database for predicting the prognosis of patients with non-small cell lung cancer [J]. Int J Biochem Cell Biol, 2020, 127(105825).
[14] LIU Y, HUANG C, LIU H, et al. Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study [J]. World J Surg Oncol, 2014, 12(138).
[15] ZHANG X X, LI R, FAN L H, et al. Prognostic predictors of radical resection of stage I-IIIB non-small cell lung cancer: the role of preoperative CT texture features, conventional imaging features, and clinical features in a retrospectively analyzed [J]. BMC Pulmonary Medicine, 2023, 23 (1): 122.
[16] ZHANG Y, QIANG J W, YE J D, et al. High resolution CT in differentiating minimally invasive component in early lung adenocarcinoma [J]. Lung Cancer, 2014, 84(3): 236-41.
[17] SHIMIZU K, YAMADA K, SAITO H, et al. Surgically curable peripheral lung carcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival [J]. Chest, 2005, 127(3): 871-8.
Copyright © 2024 Junjun Liang, Yunjin Long, Haotian Zhu, Xin Yang, Huanlong Lu, Xun Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License